wire - news in brief
« BACK
Pharmacology - Health - 27.01.2020
Pharmacology - Health - 21.01.2020
Pharmacology - Health - 20.01.2020
Health - Pharmacology - 15.01.2020
Health - Pharmacology - 09.01.2020 
One out of every two transplant recipients at risk of infection
Swiss researchers, including UNIGE, show that 50% of transplant recipients develop severe infections within a year of the operation, which can lead to death.
Pharmacology - Health - 09.01.2020
Life Sciences - Health - 07.01.2020
Pharmacology - Health - 06.01.2020
Life Sciences - Health - 20.12.2019
Life Sciences - Health - 18.12.2019
Health - Social Sciences - 17.12.2019 
Swiss Support to Healthcare Provision in Romania
From 2012-2019, Swiss TPH collaborated with the Swiss Agency for Development and Cooperation (SDC) to assist in the Romanian integration process into the EU in the area of health systems strengthening.
Health - Life Sciences - 16.12.2019
Pharmacology - Health - 16.12.2019
Pharmacology - Health - 16.12.2019
Pharmacology - Health - 13.12.2019
Pharmacology - Health - 13.12.2019
Health - Event - 13.12.2019
Pharmacology - Health - 12.12.2019
Pharmacology - Health - 11.12.2019
Health - Pharmacology - 11.12.2019
Health - Life Sciences - 10.12.2019
Health - Pharmacology - 10.12.2019
Pharmacology - Health - 09.12.2019
Health - Pharmacology - 09.12.2019
Pharmacology - Health - 08.12.2019
Health - Innovation - 06.12.2019 
Rethinking healthcare systems
ETH Zurich is planning to step up its research activities in Singapore. It aims to extend its current Future Resilient Systems programme by five years and to launch a new programme, Future Health Technologies, in the coming year. On Thursday, 5 December, ETH Zurich announced its future endeavours involving Singapore.
Pharmacology - Health - 06.12.2019
Pharmacology - Health - 05.12.2019
Health - 05.12.2019
Pharmacology - Health - 04.12.2019
Environment - Health - 03.12.2019 
"Climate Change is Becoming One of the Biggest Global Health Threats"
Climate change not only affects the environment, but also has significant consequences on global health.
Pharmacology - Health - 02.12.2019
Health - Pharmacology - 02.12.2019
Health - Pharmacology - 02.12.2019 
Improving Tuberculosis Screening in Remote Areas
Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.
Pharmacology - Health - 02.12.2019
Pharmacology - Health - 28.11.2019
Pharmacology - Health - 25.11.2019
Pharmacology - Health - 24.11.2019
Health - Pharmacology - 22.11.2019
Health - 22.11.2019
Pharmacology - Health - 18.11.2019
Pharmacology - Health - 17.11.2019
Pharmacology - Health - 15.11.2019
Pharmacology - Health - 15.11.2019
Pharmacology - Health - 15.11.2019
Pharmacology - Health - 15.11.2019
Pharmacology - Health - 13.11.2019
Health - Life Sciences - 13.11.2019 
Award for project on Heart Transplantation
This year's Johanna Dürmüller-Bol DBMR Research Award of the Department for BioMedical Research (DBMR) of the University of Bern goes to Maria-Nieves Sanz.
Pharmacology - Health - 12.11.2019
Health - Pharmacology - 12.11.2019
Health
Results 1 - 50 of 1715.
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Fo
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Fo
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or
Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or
Novartis announces EU approval of Mayzent (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
Patients & Caregivers Healthcare Professionals Society & ESG Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple s
Patients & Caregivers Healthcare Professionals Society & ESG Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple s
Genome editing at the crossroads of scandal and cure
Genetic modification of babies in China one year ago was universally condemned. At the same time, CRISPR treatments are on their way into our clinics.
Genetic modification of babies in China one year ago was universally condemned. At the same time, CRISPR treatments are on their way into our clinics.
Swiss researchers, including UNIGE, show that 50% of transplant recipients develop severe infections within a year of the operation, which can lead to death.
Novartis ligelizumab (QGE031) more effective than Xolair at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria
Patients & Caregivers Healthcare Professionals Society & ESG Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly hig
Patients & Caregivers Healthcare Professionals Society & ESG Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly hig
From 2012-2019, Swiss TPH collaborated with the Swiss Agency for Development and Cooperation (SDC) to assist in the Romanian integration process into the EU in the area of health systems strengthening.
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipipra
Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipipra
Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc
All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.
All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.
Novartis receives positive CHMP opinion for Beovu (brolucizumab) for the treatment of wet AMD
Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1
Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1
Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Roche receives CE Mark for its Accu-Chek SugarView app
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
ETH Zurich is planning to step up its research activities in Singapore. It aims to extend its current Future Resilient Systems programme by five years and to launch a new programme, Future Health Technologies, in the coming year. On Thursday, 5 December, ETH Zurich announced its future endeavours involving Singapore.
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno
Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno
Climate change not only affects the environment, but also has significant consequences on global health.
Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM
Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.
Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with baseline immunosuppressant therapy Satralizumab targets the interleukin-6 (IL-6) receptor, a potential key driver of neuromyelitis optica spectrum disorder (NMOSD) NMOSD is a rare, debilitating autoimmune disease of the central nervous system that can cause visual impairment, motor disability and even death Roche
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with baseline immunosuppressant therapy Satralizumab targets the interleukin-6 (IL-6) receptor, a potential key driver of neuromyelitis optica spectrum disorder (NMOSD) NMOSD is a rare, debilitating autoimmune disease of the central nervous system that can cause visual impairment, motor disability and even death Roche
FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
Filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Types 1, 2 or 3 SMA Roche today announced that the U.S. Foo
Filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Types 1, 2 or 3 SMA Roche today announced that the U.S. Foo
Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival in people with unresectable hepatocellular carcinoma compared with sorafenib Result
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival in people with unresectable hepatocellular carcinoma compared with sorafenib Result
Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium
Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer Follow-up data from pivotal phase III APHINITY study evaluating Perjeta plus Hercepti
Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer Follow-up data from pivotal phase III APHINITY study evaluating Perjeta plus Hercepti
Novartis PARAGON-HF analyses suggest Entresto benefit beyond HFrEF
Patients & Caregivers Healthcare Professionals Society & ESG Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compare
Patients & Caregivers Healthcare Professionals Society & ESG Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compare
New Novartis medicine Adakveo (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Patients & Caregivers Healthcare Professionals Society & ESG Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications 1 Adakveo reduced the an
Patients & Caregivers Healthcare Professionals Society & ESG Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications 1 Adakveo reduced the an
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Patients & Caregivers Healthcare Professionals Society & ESG If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active seconda
Patients & Caregivers Healthcare Professionals Society & ESG If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active seconda
CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma
First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Targeted off-the-shelf treatment represents potential new option for people with
First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Targeted off-the-shelf treatment represents potential new option for people with
CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer At three years, 88.3% of
Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer At three years, 88.3% of
This year's Johanna Dürmüller-Bol DBMR Research Award of the Department for BioMedical Research (DBMR) of the University of Bern goes to Maria-Nieves Sanz.
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
Patients & Caregivers Healthcare Professionals Society & ESG 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores
Patients & Caregivers Healthcare Professionals Society & ESG 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/AR
Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/AR
